Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Neoplasm Metastasis 3Neoplasms 2Bulbo-Spinal Atrophy, X-Linked 2Salivary Gland Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic Disease 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Ovarian Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Colorectal Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bites and Stings 1Advanced Solid Tumor 1Adenocarcinoma 1

Interventions

apalutamide 1abiraterone 1Radiosurgery 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer Metastatic Disease × abiraterone × 90 days × Clear all
NCT06832774 2026-03-25

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
192 enrolled
Genitourinary

Prostate Cancer Metastatic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡